Synthesis and properties of GuNA purine/pyrimidine nucleosides and oligonucleotides.


Journal

Organic & biomolecular chemistry
ISSN: 1477-0539
Titre abrégé: Org Biomol Chem
Pays: England
ID NLM: 101154995

Informations de publication

Date de publication:
07 12 2020
Historique:
pubmed: 13 11 2020
medline: 17 3 2022
entrez: 12 11 2020
Statut: ppublish

Résumé

We recently designed guanidine-bridged nucleic acids (GuNA), and GuNA bearing a thymine (T) nucleobase was synthesized and successfully incorporated into oligonucleotides. The GuNA-T-modified oligonucleotides possessed high duplex-forming ability towards their complementary single-stranded RNAs and were highly stable against 3'-exonuclease. Therefore, GuNA is a promissing artificial nucleic acid for therapeutic antisense oligonucleotides. We herein report the facile synthesis of GuNA phosphoramidites bearing adenine (A), guanine (G), and 5-methylcytosine (mC) nucleobases and a robust method for the preparation of GuNA-modified oligonucleotides, even with sequences having acid-sensitive purine nucleobases. Oligonucleotides modified with GuNA-A, -G, or -mC possessed high duplex-forming ability, similar to those modified with GuNA-T. Moreover, some of the GuNA-modified oligonucleotides were revealed to have high base discriminating ability compared with that of their natural counterparts. GuNA nucleosides exhibited no genotoxicity in bacterial reverse mutation assays. Thus, all GuNAs (GuNA-T, -A, -G, and -mC) are now available to be examined in therapeutic applications.

Identifiants

pubmed: 33179694
doi: 10.1039/d0ob01970d
doi:

Substances chimiques

Oligonucleotides 0

Types de publication

Journal Article Research Support, Non-U.S. Gov't

Langues

eng

Sous-ensembles de citation

IM

Pagination

9461-9472

Auteurs

Shinji Kumagai (S)

Sohyaku. Innovative Research Division, Mitsubishi Tanabe Pharma Corporation, Shonan Health Innovation Park, 2-26-1 Muraoka-Higashi, Fujisawa, Kanagawa 251-8555, Japan; 1000 Kamoshida, Aoba-ku, Yokohama 227-0033, Japan.

Hiroaki Sawamoto (H)

Sohyaku. Innovative Research Division, Mitsubishi Tanabe Pharma Corporation, Shonan Health Innovation Park, 2-26-1 Muraoka-Higashi, Fujisawa, Kanagawa 251-8555, Japan; 1000 Kamoshida, Aoba-ku, Yokohama 227-0033, Japan.

Tomo Takegawa-Araki (T)

Sohyaku. Innovative Research Division, Mitsubishi Tanabe Pharma Corporation, Shonan Health Innovation Park, 2-26-1 Muraoka-Higashi, Fujisawa, Kanagawa 251-8555, Japan; 1000 Kamoshida, Aoba-ku, Yokohama 227-0033, Japan.

Yuuki Arai (Y)

Sohyaku. Innovative Research Division, Mitsubishi Tanabe Pharma Corporation, Shonan Health Innovation Park, 2-26-1 Muraoka-Higashi, Fujisawa, Kanagawa 251-8555, Japan; 1000 Kamoshida, Aoba-ku, Yokohama 227-0033, Japan.

Shuhei Yamakoshi (S)

Sohyaku. Innovative Research Division, Mitsubishi Tanabe Pharma Corporation, Shonan Health Innovation Park, 2-26-1 Muraoka-Higashi, Fujisawa, Kanagawa 251-8555, Japan; 1000 Kamoshida, Aoba-ku, Yokohama 227-0033, Japan.

Katsuya Yamada (K)

Sohyaku. Innovative Research Division, Mitsubishi Tanabe Pharma Corporation, Shonan Health Innovation Park, 2-26-1 Muraoka-Higashi, Fujisawa, Kanagawa 251-8555, Japan; 1000 Kamoshida, Aoba-ku, Yokohama 227-0033, Japan.

Tetsuya Ohta (T)

Sohyaku. Innovative Research Division, Mitsubishi Tanabe Pharma Corporation, Shonan Health Innovation Park, 2-26-1 Muraoka-Higashi, Fujisawa, Kanagawa 251-8555, Japan; 1000 Kamoshida, Aoba-ku, Yokohama 227-0033, Japan.

Eiji Kawanishi (E)

Sohyaku. Innovative Research Division, Mitsubishi Tanabe Pharma Corporation, Shonan Health Innovation Park, 2-26-1 Muraoka-Higashi, Fujisawa, Kanagawa 251-8555, Japan; 1000 Kamoshida, Aoba-ku, Yokohama 227-0033, Japan.

Naohiro Horie (N)

Graduate School of Pharmaceutical Sciences, Osaka University, 1-6 Yamadaoka, Suita, Osaka 565-0871, Japan. obika@phs.osaka-u.ac.jp.

Takao Yamaguchi (T)

Graduate School of Pharmaceutical Sciences, Osaka University, 1-6 Yamadaoka, Suita, Osaka 565-0871, Japan. obika@phs.osaka-u.ac.jp.

Satoshi Obika (S)

Graduate School of Pharmaceutical Sciences, Osaka University, 1-6 Yamadaoka, Suita, Osaka 565-0871, Japan. obika@phs.osaka-u.ac.jp and National Institutes of Biomedical Innovation, Health and Nutrition (NIBIOHN), 7-6-8 Saito-Asagi, Ibaraki, Osaka 567-0085, Japan.

Articles similaires

1.00
Amyotrophic Lateral Sclerosis Humans Superoxide Dismutase-1 Oligonucleotides, Antisense Mutation
Animals Rats Chromatography, Liquid Tandem Mass Spectrometry Drug Discovery
Humans Biomarkers Female Male Oligonucleotides

Classifications MeSH